Global drug maker Johnson & Johnson (JNJ) announced that its COVID-19 vaccine (Ad26.COV2.S) showed 85% efficacy against Omicron-related hospitalizations in a study conducted by the South African Medical Research Council (SAMRC) on healthcare workers in South Africa. Real-World Study Results The SAMRC conducted a study among healthcare workers in South Africa from mid-November to mid-December, when the Omicron variant became dominant in the country. During the period, Omicron-related cases rose from 82% to 98% of COVID-19 cases in South Africa, as published by GISAID (Global initiative on sharing all influenza data).
https://www.tipranks.com/news/jnj-vaccine-85-effective-against-hospitalizations-in-south-africa?utm_source=advfn.com&utm_medium=referral
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Johnson and Johnson Charts.